Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma

G. Motta, M. Cea, F. Carbone, V. Augusti, E. Moran, F. Patrone, Alessio Nencioni

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The therapeutic options for B-cell non-Hodgkin 's lymphoma (NHL) have dramatically expanded with the advent of immune-based treatments. The monoclonal antibody anti-CD20 rituximab represents the best example of these advances and has quickly become incorporated into the therapeutic armamentarium for this hematological disease. In addition, other antibodies are eventually becoming part of treatment approaches to NHL. Furthermore, the role of therapeutic vaccines continues to be an important ongoing research question. Despite this success, several questions on how to optimize the use of monoclonal antibodies in NHL remain open since the best administration schedules, as well as the optimal duration of immunotherapy still have to be determined. Finally the development of resistance to treatment remains the main limit of this innovative approach, necessitating the development of strategies to circumvent resistance itself. This review will summarize the state of the art of antibody-based immunotherapy of NHL and discuss prospective approaches to improve the benefit of these treatments in patients.

Original languageEnglish
Pages (from-to)9-15
Number of pages7
JournalJournal of B.U.ON.
Volume16
Issue number1
Publication statusPublished - Jan 2011

Fingerprint

Non-Hodgkin's Lymphoma
Immunotherapy
Therapeutics
Monoclonal Antibodies
Hematologic Diseases
Antibodies
B-Cell Lymphoma
Appointments and Schedules
Vaccines
Research

Keywords

  • Apoptosis
  • Chemotherapy
  • Lymphoma
  • Monoclonal antibodies
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Radiology Nuclear Medicine and imaging

Cite this

Motta, G., Cea, M., Carbone, F., Augusti, V., Moran, E., Patrone, F., & Nencioni, A. (2011). Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. Journal of B.U.ON., 16(1), 9-15.

Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. / Motta, G.; Cea, M.; Carbone, F.; Augusti, V.; Moran, E.; Patrone, F.; Nencioni, Alessio.

In: Journal of B.U.ON., Vol. 16, No. 1, 01.2011, p. 9-15.

Research output: Contribution to journalArticle

Motta, G, Cea, M, Carbone, F, Augusti, V, Moran, E, Patrone, F & Nencioni, A 2011, 'Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma', Journal of B.U.ON., vol. 16, no. 1, pp. 9-15.
Motta G, Cea M, Carbone F, Augusti V, Moran E, Patrone F et al. Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. Journal of B.U.ON. 2011 Jan;16(1):9-15.
Motta, G. ; Cea, M. ; Carbone, F. ; Augusti, V. ; Moran, E. ; Patrone, F. ; Nencioni, Alessio. / Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. In: Journal of B.U.ON. 2011 ; Vol. 16, No. 1. pp. 9-15.
@article{7882984b01e0423a88b50a6f6eabb5c7,
title = "Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma",
abstract = "The therapeutic options for B-cell non-Hodgkin 's lymphoma (NHL) have dramatically expanded with the advent of immune-based treatments. The monoclonal antibody anti-CD20 rituximab represents the best example of these advances and has quickly become incorporated into the therapeutic armamentarium for this hematological disease. In addition, other antibodies are eventually becoming part of treatment approaches to NHL. Furthermore, the role of therapeutic vaccines continues to be an important ongoing research question. Despite this success, several questions on how to optimize the use of monoclonal antibodies in NHL remain open since the best administration schedules, as well as the optimal duration of immunotherapy still have to be determined. Finally the development of resistance to treatment remains the main limit of this innovative approach, necessitating the development of strategies to circumvent resistance itself. This review will summarize the state of the art of antibody-based immunotherapy of NHL and discuss prospective approaches to improve the benefit of these treatments in patients.",
keywords = "Apoptosis, Chemotherapy, Lymphoma, Monoclonal antibodies, Rituximab",
author = "G. Motta and M. Cea and F. Carbone and V. Augusti and E. Moran and F. Patrone and Alessio Nencioni",
year = "2011",
month = "1",
language = "English",
volume = "16",
pages = "9--15",
journal = "Journal of B.U.ON.",
issn = "1107-0625",
publisher = "Balkan Union of Oncology",
number = "1",

}

TY - JOUR

T1 - Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma

AU - Motta, G.

AU - Cea, M.

AU - Carbone, F.

AU - Augusti, V.

AU - Moran, E.

AU - Patrone, F.

AU - Nencioni, Alessio

PY - 2011/1

Y1 - 2011/1

N2 - The therapeutic options for B-cell non-Hodgkin 's lymphoma (NHL) have dramatically expanded with the advent of immune-based treatments. The monoclonal antibody anti-CD20 rituximab represents the best example of these advances and has quickly become incorporated into the therapeutic armamentarium for this hematological disease. In addition, other antibodies are eventually becoming part of treatment approaches to NHL. Furthermore, the role of therapeutic vaccines continues to be an important ongoing research question. Despite this success, several questions on how to optimize the use of monoclonal antibodies in NHL remain open since the best administration schedules, as well as the optimal duration of immunotherapy still have to be determined. Finally the development of resistance to treatment remains the main limit of this innovative approach, necessitating the development of strategies to circumvent resistance itself. This review will summarize the state of the art of antibody-based immunotherapy of NHL and discuss prospective approaches to improve the benefit of these treatments in patients.

AB - The therapeutic options for B-cell non-Hodgkin 's lymphoma (NHL) have dramatically expanded with the advent of immune-based treatments. The monoclonal antibody anti-CD20 rituximab represents the best example of these advances and has quickly become incorporated into the therapeutic armamentarium for this hematological disease. In addition, other antibodies are eventually becoming part of treatment approaches to NHL. Furthermore, the role of therapeutic vaccines continues to be an important ongoing research question. Despite this success, several questions on how to optimize the use of monoclonal antibodies in NHL remain open since the best administration schedules, as well as the optimal duration of immunotherapy still have to be determined. Finally the development of resistance to treatment remains the main limit of this innovative approach, necessitating the development of strategies to circumvent resistance itself. This review will summarize the state of the art of antibody-based immunotherapy of NHL and discuss prospective approaches to improve the benefit of these treatments in patients.

KW - Apoptosis

KW - Chemotherapy

KW - Lymphoma

KW - Monoclonal antibodies

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=79954478611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954478611&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 9

EP - 15

JO - Journal of B.U.ON.

JF - Journal of B.U.ON.

SN - 1107-0625

IS - 1

ER -